KDM1A and small cell lung carcinoma: Collectively our data provide novel insight in the mechanism contributing to heterogeneous responsiveness of SCLC to LSD1 inhibitors, and selection of mesenchymal‐like enriched subclones is likely to present a barrier to effective single‐agent responses in the clinic.